Fiche publication
Date publication
juillet 2026
Journal
European journal of nuclear medicine and molecular imaging
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
,
Pr MARTIN Thierry
,
Dr SOMME Laura
,
Dr SOMME François
,
Dr BUND Caroline
Tous les auteurs :
Frega J, Somme L, Martin T, Petit T, Salvadori J, Bund C, Somme F
Lien Pubmed
Résumé
Trastuzumab deruxtecan (T-DXd) has recently reshaped the management of HER2-low metastatic breast cancer. While pivotal trials relied on CT-based RECIST 1.1, [F]FDG PET/CT provides high diagnostic sensitivity and valuable semi-quantitative metrics, though its role in monitoring antibody-drug conjugates remains insufficiently defined. This study assessed the prognostic value of PET-derived parameters and PERCIST criteria in patients treated with T-DXd.
Mots clés
Breast cancer, HER2, PERCIST, Prognostic biomarker, Trastuzumab-deruxtecan, [18F]FDG PET/CT
Référence
Eur J Nucl Med Mol Imaging. 2026 07 1;:
